USE OF THE NEW GENETIC ENGINEERING BIOLOGICAL AGENT TOCILIZUMABIN THE TREATMENT OF RHEUMATOID ARTHRITIS
Clinical trials have provided evidence for the efficacy of tocilizumab (TCZ) used alone and in combination with basic anti-inflammatory drugs in patients with rheumatoid arthritis (RA). TCZ therapy has been found to considerably alleviate the clinical manifestations of RA, improves joint function an...
Main Authors: | E L Nasonov, E Yu Panasyuk |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA-PRESS LLC
2010-03-01
|
Series: | Современная ревматология |
Subjects: | |
Online Access: | https://mrj.ima-press.net/mrj/article/view/273 |
Similar Items
-
Safety of using genetic engineering biological agents in rheumatoid arthritis
by: N V Chichasova, et al.
Published: (2010-03-01) -
Combination therapy with leflunomide and genetic engineering biological agents
by: Nataliya Vladimirovna Chichasova, et al.
Published: (2011-06-01) -
Biological agents for endoprosthetic joint replacement in patients with rheumatoid arthritis
by: Viktoria Nikolaevna Khlaboshina, et al.
Published: (2014-12-01) -
A CURRENT VIEW ON THE PROBLEM OF RAPIDLY PROGRESSIVE RHEUMATOID ARTHRITIS
by: Dmitry Evgenyevich Karateyev
Published: (2010-06-01) -
Rheumatoid arthritis in real clinical practice: initiation of therapy with biological agents. Results of the «Computer Terminals of Self-Assessment for Patients with Rheumatic Diseases» («TERMINAL-II») project
by: V. N. Amirdzhanova, et al.
Published: (2019-09-01)